Zydus Q1: Novel Molecule Enters Phase I, Global Biosimilar Strategy To Shift?
Indian Firm Looking Forward To 505(b)(2) Sitagliptin Contribution
Zydus has begun Phase I trials for an anti-properdin drug in India while its sitagliptin franchise in US, distinct from Merck’s Januvia and Janumet, looks promising. Meanwhile MD Sharvil Patel says a biosimilars entry in developed markets is possible if certain conditions are met.
